Skip to content

Neurocrine Biosciences

US · NBIX #1162 by market cap Listed 1970
150.57 -6.02 -3.84%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Quant vs Street three independent views, side by side

StockVane factor grade
A+
Momentum strategy signal
Hold
Analyst consensus
Buy

Mostly aligned, one view stands apart.

Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.

✦ Quant Analyst Revision Trend how this is computed

Mixed
1
■ Upgrades■ Downgrades
  • 0 upgrades vs 1 downgrade among tracked analyst rating changes.
  • Most recent: Morgan Stanley moved from Buy to Hold on 2026-01-08.

Analyst consensus 19 analysts

Buy
Avg price target 207.35 +37.7%
Price target rangecurrent 150.57
Low150.00
Avg207.35
High253.00
Buy 84% Hold 16% Sell 0%
Recent ratings (25)
DateFirmAnalystRatingTarget
2026-11-13 Morgan Stanley -- Hold 191.00
2026-11-03 TD Cowen -- Buy 220.00
2026-11-03 CCORF -- Buy 220.00
2026-11-03 Wells Fargo -- Buy 200.00
2026-11-03 Bernstein -- Buy 218.00
2026-11-03 Piper Sandler -- Buy 215.00
2026-11-03 BofA Securities -- Buy --
2026-11-03 Wedbush -- Buy 186.00
2026-11-03 Morgan Stanley -- Hold 185.00
2026-11-03 Deutsche Bank -- Hold 175.00
2026-11-03 Guggenheim -- Buy 224.00
2026-11-03 Oppenheimer -- Buy 230.00
2026-11-02 Cantor Fitzgerald -- Buy 215.00
2026-11-02 Morgan Stanley -- Hold 183.00
2026-11-02 BMO Capital -- Hold 150.00
2026-11-02 RBC Capital -- Buy 190.00
2026-11-02 J.P. Morgan -- Buy --
2026-10-16 Needham -- Buy 204.00
2026-10-13 Wells Fargo -- Buy 200.00
2026-10-13 RBC Capital -- Buy 187.00
2026-10-12 BMO Capital -- Hold 150.00
2026-10-09 Piper Sandler -- Buy 210.00
2026-10-09 BofA Securities -- Buy 214.00
2026-10-08 RBC Capital -- Buy 187.00
2026-10-05 Guggenheim -- Buy 207.00

Price target trend monthly average, last 3 years

Recent rating changes

DateFirmChangeTarget
2026-01-08 Morgan Stanley Buy → Hold 175.00

Earnings history price reaction on the day

PeriodReport dateSessionOptions expectedActual move
2026/Q3 2026-11-02 After close ±9.60% +13.42% (beat)
2026/Q2 2026-07-30 After close ±8.09% -10.08% (beat)
2026/Q1 2026-05-05 After close ±7.44% +8.86% (beat)
2025/Q4 2026-02-11 After close ±6.70% -10.43% (beat)
2025/Q3 2025-10-28 After close ±8.87% -6.35% (in line)
2025/Q2 2025-07-30 After close ±9.19% -6.24% (in line)
2025/Q1 2025-05-05 After close ±12.38% +8.36% (in line)
2024/Q4 2025-02-06 After close ±7.76% -18.53% (beat)
2024/Q3 2024-10-30 -- ±8.10% +7.01% (in line)
2024/Q2 2024-08-01 -- ±16.25% +8.18% (in line)
2024/Q1 2024-05-01 -- ±7.33% +3.99% (in line)
2023/Q4 2024-02-07 -- ±7.12% -4.67% (in line)

"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.

Quote time 2026-11-20 20:02:19 · For reference only, not investment advice and not tailored to your situation.

Neurocrine Biosciences discussion 0 comments

Add a comment